Drug Trial Radar · NCT06009029
SBRT Combined With Zimberelimab (GLS-010) in Locally Advanced Pancreatic Cancer (SPARK-1 Study)
Last checked: Nov 19, 2026Latest source record: Aug 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
96
Planned (sponsor's estimate)
Start
Aug 2023
Primary completion
Jul 2026
Study completion Jul 2027
Sponsor
- Lead sponsor
- Peking University Third HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 24, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is designed to investigate the efficacy and safety of patients with locally advanced pancreatic cancer by SBRT combined with Zimberelimab(GLS-010).
Conditions
- Locally Advanced Pancreatic Cancer
Interventions
Stereotactic body radiation(SBRT)Radiation
SBRT: 7-10 Gy/F, 5 doses Zimberelimab: 240mg d1 iv Q21D, within 7 days after SBRT completion. Receiving a minimum of six cycles of treatment, or disease progression or intolerable toxic side effects.
Zimberelimab (GLS-010)Drug
Zimberelimab (GLS-010),240mg d1 iv Q21D
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survival (OS)Time frame: 2 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.